Adial Pharmaceuticals Inc. | MANAGEMENT
16087
page-template-default,page,page-id-16087,page-child,parent-pageid-16092,ajax_fade,page_not_loaded,,qode-theme-ver-16.2.1,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

MANAGEMENT

William B. Stilley
Chief Executive Officer and President

William B. Stilley has served as our Chief Executive Officer since December 2010. Prior to joining Adial Pharmaceuticals, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. (NASDQ CLDA), where he worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the Company’s vasodilator drug for myocardial stress imaging.Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps.

 

Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. Until recently, he guest lectured at the Darden School of Business in two courses on the management of life science companies. He currently serves on the Board of Virginia BIO, the statewide biotechnology organization. He also holds a patent for Stedivaze®, which is currently in Phase 3 clinical development.

Joseph Truluck
Chief Operating Officer & Chief Financial Officer

Joseph Truluck was appointed as our Chief Operating Officer and CFO in 2017 and, since May 2016, has been our VP Operations and Finance. Since January 2013, Mr. Truluck has served as the VP Operations and Finance at Adenosine Therapeutics, after the company reacquired its major drug development program. As VP, Operations & Finance, at Adenosine Therapeutics, Mr. Truluck has overseen the operations of the business, including seeing to completion a project to merge and analyze two partially completed Phase 3 trials to constitute a single trial. Previously, Mr. Truluck served as the Operations Manager of Adenosine Therapeutics’ until its purchase by Clinical Data (NASDAQ:CLDA).   He is the co-founder and former VP Operations and Finance for Beonten, Inc., a software development company. Beonten’s goal was the creation of a software platform for knowledge management and sharing. Beonten was a Semi-Finalist in the prestigious MIT 100K business plan competition. Mr. Truluck has a MBA from Tulane University with a concentration in Finance and an MA in Philosophy at the University of Virginia, with a thesis in the area of modal semantics.

Tomasz H. Zastawny, D.Sc., Ph.D.
Chief Development Officer

 

 

Dr. Zastawny has served as our Chief Development Officer since July 2017. Dr. Zastawny has over 25 years of experience in all aspects of pharmaceutical product development, including regulatory and regulatory strategy, managing, planning, designing and conducting domestic and international clinical studies compliance, and preparation of products for commercial launch. He has led or otherwise participated in more than 150 clinical trials, both domestic and internationally. Recently, he has been the CEO of ECRC, LLC, which he founded in 2008 and which provides consulting services to a number of US and international biopharmaceutical companies, with a focus on the development of strategy and the commercialization of pharmaceuticals and medical devices. He is also a partner in Quark Ventures, a life sciences VC fund. During his career Dr. Zastawny has served in numerous senior positions with responsibility for drug development, most recently serving as VP of Drug Development at Amrita Therapeutics and as a VP of R&D for Boston Therapeutics. He began his career in the contract research industry, including serving as the President, Central & Eastern European Units at PRA International, a global CRO, where he was responsible for the all clinical trials in the region.

 

Dr. Zastawny is a frequent speaker at numerous domestic and international conferences, is the author and co-author of over 80 articles and publications and co-author of the book on clinical aspects of drug development.  He received his Ph.D. in Medical Sciences at Nicolaus Copernicus University in Bydgoszcz, Poland and his D.Sc. in Biochemistry at the Polish Academy of Science in Warsaw, Poland.

 

Dr. Zastawny currently serves as our consultant on a part-time basis; however, upon the closing of a financing,  he will join the company as an officer and employee